User profiles for C. Brumme
 | Chanson BrummeAssistant Professor, Faculty of Medicine, University of British Columbia Verified email at bccfe.ca Cited by 9775 |
Adaptation of HIV-1 to human leukocyte antigen class I
… c, d, In vitro competition assays between NL4-3 wild-type virus and I135X viral variants (I135T
(c) and … In HIV, HLA-B*1801 is associated with high viraemia in C clade but not in B clade …
(c) and … In HIV, HLA-B*1801 is associated with high viraemia in C clade but not in B clade …
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
… above C trough – 1 SD were at as low a risk as those with 0%–<20% prescription-refill
percentages. The risk for individuals with 1 of 2 drug concentrations above C trough – 1 SD fell …
percentages. The risk for individuals with 1 of 2 drug concentrations above C trough – 1 SD fell …
[HTML][HTML] Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection
Deep sequencing technologies have the potential to transform the study of highly variable
viral pathogens by providing a rapid and cost-effective approach to sensitively characterize …
viral pathogens by providing a rapid and cost-effective approach to sensitively characterize …
HLA-B57/B* 5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong …
Human immunodeficiency virus type 1 (HIV-1) elite controllers (EC) maintain viremia below
the limit of commercial assay detection (<50 RNA copies/ml) in the absence of antiviral …
the limit of commercial assay detection (<50 RNA copies/ml) in the absence of antiviral …
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals
ZL Brumme, J Goodrich, HB Mayer… - The Journal of …, 2005 - academic.oup.com
ObjectiveWe wished to characterize the epidemiological and clinical correlates of CXCR4-using
human immunodeficiency virus type 1 (HIV-1) (“X4 variants”) in a cross-sectional …
human immunodeficiency virus type 1 (HIV-1) (“X4 variants”) in a cross-sectional …
[HTML][HTML] Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1–Specific CD8+ T Cells
H Streeck, ZL Brumme, M Anastario, KW Cohen… - PLoS …, 2008 - journals.plos.org
… at 4 C. Peptides were added directly to the wells at a final concentration of 14 μg/ml. Cells
were added to the wells at 50,000–100,000 cells/well. The plates were incubated at 37 C, 5% …
were added to the wells at 50,000–100,000 cells/well. The plates were incubated at 37 C, 5% …
Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T …
Primary HIV-1 infection (PHI) is marked by a flu-like syndrome and high levels of viremia
that decrease to a viral set point with the first emergence of virus-specific CD8 + T-cell …
that decrease to a viral set point with the first emergence of virus-specific CD8 + T-cell …
Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool
CK Woods, CJ Brumme, TF Liu, CKS Chui… - Journal of clinical …, 2012 - Am Soc Microbiol
… Panels A to C show positions called mixtures by human visual inspection but not by RECall.
Panels D to F show positions called mixtures by RECall but not by human interpretation. In …
Panels D to F show positions called mixtures by RECall but not by human interpretation. In …
[HTML][HTML] HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins
Background Despite the extensive genetic diversity of HIV-1, viral evolution in response to
immune selective pressures follows broadly predictable mutational patterns. Sites and …
immune selective pressures follows broadly predictable mutational patterns. Sites and …
[HTML][HTML] Definition of the viral targets of protective HIV-1-specific T cell responses
Background The efficacy of the CTL component of a future HIV-1 vaccine will depend on the
induction of responses with the most potent antiviral activity and broad HLA class I restriction…
induction of responses with the most potent antiviral activity and broad HLA class I restriction…